• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection
  • News
  • Opinion
  • About
  • Glossary
  • PV Forum

Real World Evidence (RWE): Predictive Analytics to Impact Patient Safety

February 23, 2018 by Ale Vazquez-Gragg, MD Leave a Comment

Real World Evidence and SafetyThe use of new analytical tools applied to large, diverse, complex data sets, so called “big data”, the development of devices to track and gather real-time healthcare data and information and the use of digital media are on the increase in the healthcare environment and have the potential to be of great value if harnessed and utilized appropriately.

The current main system for keeping track of dangerous side effects of prescription drugs is deeply flawed according to the Institute for Safe Medications Practices (ISMP). The study conducted by the ISMP found that only about half of reports of serious side effects submitted by manufacturers met basic standards for completeness.

No longer just a sideline used to fill knowledge gaps, the evidence generated from real-world data (RWD) is rapidly becoming an integral component of product evidence strategies. However, the growing volumes and heterogeneity of real-world data sources are creating increasingly inefficient and chaotic analytic environments and as a result, new approaches for database analyses are needed.

Real-world evidence (RWE) allows companies to make more informed and reliable strategic decisions earlier when it comes to protect patient safety. Another value added is converting RWD into valuable RWE that offers great scientific and patient benefit trials as well as shortening phase III to accelerate the approval procedures. These benefits include improving the ability to positively impact patient outcomes through understanding of disease characteristics and treatment patterns, enhancing medicines compliance and aiding in interpreting treatment outcomes for individual patients. It also enables organizations to demonstrate health outcomes and support the case for the value of their products to health authorities, payers, health care providers and patients.

The opportunity to use these technologies and derive their potential benefits to assess the efficacy and effectiveness of therapeutic options is in its infancy. Although they could be the key to establishing a credible new generation of fit-for-purpose RWE, pharmaceutical companies have been cautiously investigating the use of the various technologies that contribute to big data collection (e.g., social media, electronic health records, insurance data claim databases) and the application of analytics to these data sets including pharmacovigilance to assess side effects. The case for accessing and evaluating the plethora of different data sets is clear. However, while the opportunity is large, exploiting the value requires the appropriate governance, knowledge and analytics capabilities to stay within the acceptable tolerance levels for compliance and reputation risk management. Pharmacovigilance departments will become a key element within the organizations.

Questions have been raised as to how best to deploy innovative collection and analytic technologies to maximize their effectiveness. Approaches such as the Advancing Medical Innovation initiative encourage the FDA to identify opportunities to use big data to streamline and support pre- and post-approval activities. In Europe, collaborative projects in the area of post-authorization efficacy studies have identified the need for companies and agencies to be able to measure safety and effectiveness in the real-world use of new medicines.

This is mirrored by the need for pharmaceutical and biotech companies to quickly adapt their pharmacovigilance departments into cross-functional teams to strategically make decisions regarding how new medicines will be used in the real world and to confirm the expected benefit and value, often derived largely from controlled clinical studies. In a rapidly changing regulatory environment, with a diverse set of data sources, contractual mechanisms and data privacy requirements, the capabilities needed to extract the value from the data become strategic in their own right.

Over the last years the potential of real-world data and analytics has been discussed as opportunities to enhance patient engagement, reduce uncertainty in the development and approval space, as well to serve as a natural process for the collection of benefit and risk data post-authorization. Collecting data from a mix of evidentiary experiences would support novel flexible regulatory pathways that accelerate reviews and access to medicines, and therefore, will likely play a key role in transforming medicine development and access over the next decade.

Are we ready for this?

Ale Vazquez-Gragg, MD
Ale Vazquez-Gragg, MD

Ale is the VP, Head Global Patient Safety at Intarcia Therapeutics, Inc.

Filed Under: Opinion

About Ale Vazquez-Gragg, MD

Ale is the VP, Head Global Patient Safety at Intarcia Therapeutics, Inc.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Subscribe in a reader

Featured News / Posts

Analysis Of Textual Data May Complement Traditional Pharmacovigilance

According to a well-written systematic review on the application of natural … [Read More...] about Analysis Of Textual Data May Complement Traditional Pharmacovigilance

Machine Learning and Pharmacovigilance

Machine learning (ML) is becoming increasingly available to everyone, including … [Read More...] about Machine Learning and Pharmacovigilance

Post-Randomization vs On Treatment Made All the Difference

Post-Randomization vs On Treatment Made All the Difference

The Food and Drug Administration (FDA) recently requested withdraw of Belviq® … [Read More...] about Post-Randomization vs On Treatment Made All the Difference

Pharmacovigilance Audits/Inspections and PV Analytics!

Disclaimer: This article is written by a Safety Physician to provide … [Read More...] about Pharmacovigilance Audits/Inspections and PV Analytics!

Artificial Intelligence in pharmacovigilance? What a challenge!

Abstract Pharmaceutical industry, and more particularly pharmacovigilance, … [Read More...] about Artificial Intelligence in pharmacovigilance? What a challenge!

Knowledge Graphs,  Semantic Web and Drug Safety

Knowledge Graphs, Semantic Web and Drug Safety

Second part of: Mining PubMed for Drug Induced Acute Kidney Injury When I … [Read More...] about Knowledge Graphs, Semantic Web and Drug Safety

Review of Safety in FDA Medical Reviews

Review of Safety in FDA Medical Reviews

Analysis of the latest review of safety sections for new drug applications (NDAs … [Read More...] about Review of Safety in FDA Medical Reviews

Mining PubMed for Drug Induced Acute Kidney Injury

Mining PubMed for Drug Induced Acute Kidney Injury

Enhancing signal detection capabilities beyond regular literature … [Read More...] about Mining PubMed for Drug Induced Acute Kidney Injury

Top 7 Predictive Model Applications in Drug Safety and Pharmacovigilance

As drug safety and pharmacovigilance organizations develop more sophisticated … [Read More...] about Top 7 Predictive Model Applications in Drug Safety and Pharmacovigilance

The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

Peter J Pitts, President of the Center for Medicine in the Public Interest, and … [Read More...] about The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

  • Disproportional Recording vs Disproportional Reporting
  • Deep Learning, Machine Learning, and Artificial Intelligence – What are the Differences?
  • How Organizations Use Social Media For Pharmacovigilance

RSS From Nature journal

  • Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice
  • Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
  • Effect of date molasses on levetiracetam pharmacokinetics in healthy rats
  • Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
  • Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study

Copyright © 2023 · News Pro on Genesis Framework · WordPress · Log in